Skip to main content

Advertisement

SpringerLink
Log in

Some recent advances in multiple sclerosis

  • Neurological Update
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

In this article, we review some of the key advances in multiple sclerosis (MS) over the last 3 years. Significant progress has been made in understanding the genetics and pathogenesis of MS. The classification of MS phenotypes has been revised and the landscape of therapeutics is rapidly evolving. We provide a practical summary of the main developments for the practising neurologist.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Rocca MA, Messina R, Filippi M (2013) Multiple sclerosis imaging: recent advances. J Neurol 260:929–935

    Article  PubMed  Google Scholar 

  2. Belbasis L, Bellow V, Evangelou E, Ioannidis JP, Tzoulaki I (2015) Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses. Lancet Neurol 14:263–273

    Article  PubMed  Google Scholar 

  3. Dendrou CA, Fugger L, Friese MA (2015) Immunopathology of multiple sclerosis. Nat Rev Immunol 15:545–558

    Article  CAS  PubMed  Google Scholar 

  4. Jersild C, Svejgaard A, Fog T (1972) HL-A antigens and multiple sclerosis. Lancet 299:1240–1241

    Article  Google Scholar 

  5. Sawcer S, Franklin RJM, Ban M (2014) Multiple sclerosis genetics. Lancet Neurol 13:700–709

    Article  CAS  PubMed  Google Scholar 

  6. International Multiple Sclerosis Genetics Consortium (IMSGC) (2013) Advances in genetics of MS: Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet 45:1353–1360

    Article  Google Scholar 

  7. Farh KKH, Marson A, Zhu J et al (2015) Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature 518:337–343

    Article  CAS  PubMed  Google Scholar 

  8. International Multiple Sclerosis Genetics Consortium (IMSGC) (2013) Network-based multiple sclerosis pathway analysis with GWAS data from 15,000 cases and 30,000 controls. Am J Hum Genet 92:854–865

    Article  Google Scholar 

  9. Hauser SL, Waubant E, Arnold DL et al (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358:676–88108

    Article  CAS  PubMed  Google Scholar 

  10. Srivastava R, Aslam M, Kalluri SR, Schirmer L, Buck D, Tackenberg B et al (2012) Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med 367:115

    Article  CAS  PubMed  Google Scholar 

  11. Brickshawana A, Hinson SR, Romero MF et al (2014) Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative study. Lancet Neurol 13:795–806

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Nerrant E, Salsac C, Charif M et al (2014) Lack of confirmation of anti-inward rectifying potassium channel 4.1 antibodies as reliable markers of multiple sclerosis. Mult Scler 20:1699–1703

    Article  CAS  PubMed  Google Scholar 

  13. Hemmer B (2015) Antibodies to the inward rectifying potassium channel 4.1 in multiple sclerosis: different methodologies—conflicting results? Mult Scler 21:537–539

    Article  CAS  PubMed  Google Scholar 

  14. Filippi M, Rocca MA, Lassmann H (2014) KIR4.1: another misleading expectation in multiple sclerosis? Lancet Neurol 13:753–755

    Article  CAS  PubMed  Google Scholar 

  15. Lublin FD, Reingold SC, Cohen JA et al (2014) Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83:278–286

    Article  PubMed  PubMed Central  Google Scholar 

  16. Calabresi PA, Kieseier BC, Arnold DL et al (2014) Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol 13:657–665

    Article  CAS  PubMed  Google Scholar 

  17. Hunt D, Kavanagh D, Drummond I, Weller B, Bellamy C, Overell J, Evans S, Jackson A, Chandran S (2014) Thrombotic microangiopathy associated with interferon beta. N Engl J Med 370:1270–1271

    Article  PubMed  PubMed Central  Google Scholar 

  18. Medicines and Healthcare products Regulatory Agency (2014) Interferon-beta: risk of thrombotic microangiopathy and risk of nephrotic syndrome. https://www.gov.uk/drug-safety-update/interferon-beta-risk-of-thrombotic-microangiopathy-and-risk-of-nephrotic-syndrome. Accessed 20th Jan 2016

  19. Fox RJ, Miller DH, Phillips JT et al (2012) Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 367:1087–1097

    Article  CAS  PubMed  Google Scholar 

  20. Gold R, Kappos L, Arnold DL et al (2012) Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 367:1098–1107

    Article  CAS  PubMed  Google Scholar 

  21. European medicines agency (2015) Updated recommendations to minimise the risk of the rare brain infection PML with Tecfidera. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/10/news_detail_002423.jsp&mid=WC0b01ac058004d5c1. Accessed 20th January 2016

  22. McGuigan C, Craner M, Guadagno J, Kapoor R, Mazibrada G, Molyneux P, Nicholas R, Palace J, Pearson OR, Rog D, Young CA (2015) Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry. doi:10.1136/jnnp-2015-311100. (Published Online First: 22 October 2015)

  23. EMA confirms recommendations to minimise risk of brain infection PML with Tysabri. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Tysabri_20/Opinion_provided_by_Committee_for_Medicinal_Products_for_Human_Use/WC500202394.pdf. Accessed 22nd Mar 2016

  24. O’Connor PW, Goodman A, Kappos L, Lublin FD, Miller DH, Polman C, Rudick RA, Aschenbach W, Lucas N (2011) Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 76:1858–1865

    Article  PubMed  Google Scholar 

  25. Sorensen PS, Koch-Henriksen N, Petersen T, Ravnborg M, Oturai A, Sellebjerg F (2014) Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients. J Neurol 261:1170–1177

    Article  CAS  PubMed  Google Scholar 

  26. Fox RJ, Cree BA, De Sèze J, Gold R, Hartung HP et al (2014) MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology 82:1491–1498

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. New recommendations to minimise risks of the rare brain infection PML and a type of skin cancer with Gilenya. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/12/news_detail_002447.jsp&mid=WC0b01ac058004d5c1. Accessed 23rd Mar 2016

  28. Cohen JA, Coles AJ, Arnold DL et al (2012) Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380:1819–1828

    Article  CAS  PubMed  Google Scholar 

  29. Coles AJ, Fox E, Vladic A et al (2012) Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology 78:1069–1078

    Article  CAS  PubMed  Google Scholar 

  30. Wade DT, Young CA, Chaudhuri KR, Davidson DLW (2002) A randomised placebo controlled exploratory study of vitamin B-12, lofepramine, and l-phenylalanine (the “Cari Loder regime”) in the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 73:246–249

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Sharafaddinzadeh N, Moghtaderi A, Kashipazha D, Majdinasab N, Shalbafan B (2010) The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomised placebo-controlled trial. Mult Scler 16:964–969

    Article  CAS  PubMed  Google Scholar 

  32. Zamboni P, Galeotti R, Menegatti E et al (2009) A prospective open-label study of endovascular treatment of chronic cerebrospinal venous insufficiency. J Vasc Surg 50:1348–1358

    Article  PubMed  Google Scholar 

  33. Siddiqui AH, Zivadinov R, Benedict RHB et al (2014) Prospective randomized trial of venous angioplasty in MS (PREMiSe). Neurology 83:441–444

    Article  PubMed  PubMed Central  Google Scholar 

  34. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A (2006) Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 296:2832–2838

    Article  CAS  PubMed  Google Scholar 

  35. Ascherio A, Munger KL (2007) Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. Ann Neurol 61:504–513

    Article  CAS  PubMed  Google Scholar 

  36. Stein MS, Liu Y, Gray OM, Baker JE, Kolbe SC, Ditchfield MR, Egan GF, Mitchell PJ, Harrison LC, Butzkueven H, Kilpatrick TJ (2011) A randomized trial of high-dose vitamin D2 in relapsing remitting multiple sclerosis. Neurology 77:1611–1618

    Article  CAS  PubMed  Google Scholar 

  37. Mosayebi G, Ghazavi A, Ghasami K, Jand Y, Kokhaei P (2011) Therapeutic effect of vitamin D3 in multiple sclerosis patients. Immunol Invest 40:627–639

    Article  CAS  PubMed  Google Scholar 

  38. Shaygannejad V, Janghorbani M, Ashtari F, Dehghan H (2012) Effects of adjunct low-dose vitamin D on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial. Mult Scler Int 2012:452541

    PubMed  PubMed Central  Google Scholar 

  39. Soilu-Hanninen M, Aivo J, Lindstrom BM et al (2012) A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 83:565–571

    Article  PubMed  Google Scholar 

  40. Aivo J, Lindsrom BM, Soilu-Hanninen M (2012) A randomised, double-blind, placebo-controlled trial with vitamin D3 in MS: subgroup analysis of patients with baseline disease activity despite interferon treatment. Mult Scler Int 2012:802796

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Røsjø E, Steffensen LH, Jørgensen L, Lindstrøm JC, Šaltytė Benth J, Michelsen AE, Aukrust P, Ueland T, Kampman MT, Torkildsen Ø, Holmøy T (2015) Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis. J Neurol 262:2713–2721

    Article  PubMed  Google Scholar 

  42. Steffensen LH, Jørgensen L, Straume B, Mellgren SI, Kampman MT (2011) Can vitamin D supplementation prevent bone loss in persons with MS? A placebo-controlled trial. J Neurol 258:1624–1631

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Pihl-Jensen G, Frederiksen JL (2015) 25-Hydroxyvitamin D levels in acute monosymptomatic optic neuritis: relation to clinical severity, paraclinical findings and risk of multiple sclerosis. J Neurol 262:1646–1654

    Article  CAS  PubMed  Google Scholar 

  44. Malik MT, Healy BC, Benson LA, Kivisakk P, Musallam A, Weiner HL, Chitnis T (2014) Factors associated with recovery from acute optic neuritis in patients with multiple sclerosis. Neurology 82:2173–2179

    Article  PubMed  PubMed Central  Google Scholar 

  45. Sedel F, Papeix C, Bellanger A, Touitou V, Lebrun-Frenay C, Galanaud D, Gout O, Lyon-Caen O, Tourbah A (2015) High doses of biotin in chronic progressive multiple sclerosis: a pilot study. Mul Scler Relat Disord 4:159–169

    Article  Google Scholar 

  46. Chataway J, Schuerer N, Alsanousi A et al (2014) Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet 383:2213–2221

    Article  CAS  PubMed  Google Scholar 

  47. ClinicalTrials.gov (2015) MS-SMART: multiple sclerosis-secondary progressive multi-arm randomisation trial. https://clinicaltrials.gov/ct2/show/NCT01910259. Accessed 20th Jan 2016

  48. Kappos L, Wiendl H, Selmaj K, Arnold DL, Havrdova E et al (2015) Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis. NEJM 373:1418–1428

    Article  CAS  PubMed  Google Scholar 

  49. Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, Waldmann TA, McFarland H, Henkart PA, Martin R (2006) Regulatory CD56 super(bright) natural killer cells mediate immunomodulatory effects of IL-2R α-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci 103:5941–5946

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Giovannoni G (2015) Help us find out if we can treat multiple sclerosis with antiviral drugs. https://www.crowdacure.com/projects/researching-the-role-of-viruses-in-causing-multiple-sclerosis. Accessed 20th Jan 2016

Download references

Author information

Authors and Affiliations

  1. Addenbrooke’s Hospital, Hills Road, Cambridge, CB2 0QQ, UK

    Claire McCarthy & John Thorpe

  2. Queen Elizabeth Hospital, Gayton Road, King’s Lynn, PE30 4ET, UK

    Claire McCarthy

  3. Peterborough City Hospital, Bretton Gate, Peterborough, PE3 9GZ, UK

    John Thorpe

Authors
  1. Claire McCarthy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John Thorpe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Claire McCarthy.

Ethics declarations

Conflict of interests

Dr. McCarthy has obtained funding to attend a scientific meeting from Biogen Idec and was an investigator on the phase II and III alemtuzumab trials. Dr. Thorpe has obtained funding to attend scientific meetings from Biogen Idec, GlaxoSmithKline, Merck Serono, Novartis Pharmaceuticals and Teva UK. He has received a lecturing fee from Biogen Idec.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

McCarthy, C., Thorpe, J. Some recent advances in multiple sclerosis. J Neurol 263, 1880–1886 (2016). https://doi.org/10.1007/s00415-016-8124-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-016-8124-1

Keywords

Search

Navigation